ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Languid Uptake of Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Infections and Continued Reliance on Polymyxins.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Adaptive colistin resistance dynamics inMicrobiology spectrum · 2026Article
- Drug screening to identify compounds to eliminateiScience · 2026Article
- Synergistic activity of ceftazidime/avibactam combined with aztreonam against MBL-producingFrontiers in cellular and infection microbiology · 2026Article
- Molecular characteristics and antibiotic resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa in Nanning, China.BMC microbiology · 2024Article
- Risk Factors and Outcomes of Patients with Carbapenem-ResistantInfection and drug resistance · 2023Article
- Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion.Antibiotics (Basel, Switzerland) · 2022Review
- Review
- The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations.Antibiotics (Basel, Switzerland) · 2022Review
- Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections.The Journal of antimicrobial chemotherapy · 2021Article
- Cost Analysis of New Antibiotics to Treat Multidrug-Resistant Bacterial Infections: Mind the Gap.Infectious diseases and therapy · 2021Article
- A First Draft of the History of Treating Coronavirus Disease 2019: Use of Repurposed Medications in United States Hospitals.Open forum infectious diseases · 2021Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.